Investigation Launched Against PepGen Inc. by Pomerantz LLP
New York, April 14, 2025 – In a recent press release, Pomerantz LLP, a renowned securities law firm, announced that it is investigating potential claims on behalf of investors of PepGen Inc. (PepGen or the Company) (NASDAQ: PEPG). The investigation comes after allegations of possible securities laws violations.
Background on PepGen Inc.
PepGen is a clinical-stage biotechnology company focused on developing novel therapies for genetic disorders. The Company’s most advanced program, PEPA-101, is designed to treat Sanfilippo syndrome, a rare and progressive lysosomal storage disorder.
The Allegations
The securities class action lawsuit alleges that PepGen and certain of its executives and directors made materially false and misleading statements regarding the Company’s business, operational, and financial prospects. Specifically, the complaint alleges that the defendants failed to disclose material information regarding the progress of PEPA-101’s clinical trials and the Company’s financial condition.
Impact on Investors
The investigation may have significant implications for investors who purchased or otherwise acquired PepGen securities between specific dates. These investors may be able to recover their losses if it is determined that the defendants violated securities laws. For more information, investors are encouraged to contact Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 154.
Impact on the World
The potential fallout from this investigation could have far-reaching consequences. If the allegations are proven true, it could deter investors from supporting biotech companies, potentially hindering the progress of new treatments and therapies. Moreover, it may result in increased regulatory scrutiny of the biotech sector as a whole.
Conclusion
The investigation into PepGen Inc. by Pomerantz LLP is a reminder of the importance of transparency and accuracy in corporate communications. As investors, it is crucial to stay informed about the companies we invest in, and to hold those responsible for any potential misrepresentations accountable. For more information, please contact Danielle Peyton at newaction@pomlaw.com or call 646-581-9980, ext. 154.
- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc.
- Allegations of possible securities laws violations.
- Background on PepGen and its most advanced program, PEPA-101.
- The securities class action lawsuit alleges materially false and misleading statements.
- Potential implications for investors who purchased or otherwise acquired PepGen securities.
- Possible deterrent effect on investors and increased regulatory scrutiny of the biotech sector.
- Contact information for investors interested in the investigation.
